ARTVArtiva Biotherapeutics, Inc.
$6.95+132% 1Y
$6.95
$2.7452 weeks$13.39
Price
+132%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for ARTV today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$330.9M
1 year+132%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $0 (−100% year on year) and net income −$84M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 11, 2026On September 8, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Director or officer change · Form 8-K
- Aug 6, 2026Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
- Jul 22, 2026Artiva Biotherapeutics, Inc. (the “Company”) today announced that the expected date for the Company’s 2026 annual meeting of stockholders (the “Annual Meeting”) is September 8, 2026, which is more than 70 days after the one-year anniversary of the Company’s 2025 annual meeting of stockholders.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry